Of note, the effect of the SGLT2 inhibitors on albuminuria was greater in patients with diabetes than in patients without diabetes and in patients with diabetic nephropathy than in patients with other etiologies of CKD [34]. This evidence concerns the gene SLC5A2 and chronic kidney disease.